



Luxembourg, 20 December 2024

## Environmental and Social Completion Sheet (ESCS)

### Overview

Project Name:	ALGEA (EGFF)
Project Number:	2018-0532
Country:	Austria
Project Description:	The Company is a biopharmaceutical company developing therapeutic solutions for the treatment of respiratory and ophthalmic conditions. The eligible investment plan includes research and development (R&D) and related expenses to finance the development of the Company's two proprietary biotechnology platforms during the investment period 2019-2022.

### Summary of Environmental and Social Assessment at Completion

**EIB notes the following Environmental and Social performance and key outcomes at Project Completion.**

The project's activities are not listed in the annexes of the EU Directive 2014/52/EU amending 2011/92/EU. The project has not resulted in any residual environmental impact as it has been carried out in existing and authorised research facilities. The promoter's operating procedures are in-line with best industry standards and are subject to regular external audits.

#### Other Environmental and Social Aspects

The promoter's R&D practices comply with relevant national and EU regulations (directives 2001/83/EC, 2005/28/EC, 2001/20/EC and Good Clinical Practice, as applicable) and the promoter maintains adequate internal procedures and management practices.

The promoter is committed to animal welfare and their responsible use for scientific purposes; the promoter complies with the EU Directive 2010/63/EU.

#### Summary opinion of Environmental and Social aspects at completion:

EIB is of the opinion, based on reports from the promoter, that the Project has been implemented in line with EIB Environmental and Social Standards, applicable at the time of appraisal.